Chen, Candace – Trademark Portfolio
Entity Type: 01
Chen, Candace holds 45 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 41 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 9 trademarks are registered and 1 is pending. Notable registered marks include 888, CAMELOT, FACELUBE, LUCKY DRAGON, and FOR A MAN'S MAN. The owner is based in Los Angeles, CA.
3710 Avalon Blvd
Los Angeles, CA 90011
Showing of trademarks Trademarks
Trademark Classifications
Chen, Candace's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Chen, Candace have?
Chen, Candace has 45 U.S. trademarks filed with the USPTO. Of these, 9 registered, 1 pending, 20 abandoned, 15 cancelled.
What trademark classes does Chen, Candace file in?
Chen, Candace files trademarks across 3 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Chen, Candace's most well-known trademarks?
Chen, Candace's registered trademark portfolio includes well-known marks such as 888, CAMELOT, FACELUBE, LUCKY DRAGON, and FOR A MAN'S MAN. These are among 9 currently registered trademarks in the portfolio.
What is Chen, Candace's trademark registration success rate?
Chen, Candace has a 20% trademark registration rate, with 9 out of 44 resolved applications resulting in successful registration. Currently, 1 application is pending review.